Medicare Coverage for GLP-1 Medications: What Seniors Need to Know

Disclaimer: Insurance and cost information changes frequently. Always verify current coverage details with your insurer and prescriber.

What Medicare Currently Covers

The short answer for most Medicare beneficiaries seeking GLP-1 medications for weight loss alone is this: Medicare does not cover them. But the situation is more nuanced than that blanket statement suggests, and for many seniors — particularly those managing Type 2 diabetes — coverage may already be available through your Part D plan.

Medicare Part D covers semaglutide (Ozempic) and tirzepatide (Mounjaro) when they are prescribed for the management of Type 2 diabetes. Both drugs are FDA-approved for that indication, and most Part D formularies include at least one of them, typically in Tier 3 or Tier 4. The coverage is tied to the diagnosis code on your prescription — if your physician lists diabetes as the indication, the drug should be processed through your Part D plan.

Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide for obesity) are a different story. These FDA-approved weight-loss formulations are explicitly excluded from Medicare coverage under current federal law. Even if your Part D plan wanted to cover them, it is legally prohibited from doing so for the weight-loss indication.

As of 2025, out-of-pocket costs for Medicare beneficiaries who do have Part D coverage for a GLP-1 are more manageable than they were before the Inflation Reduction Act. The IRA introduced a $2,000 annual out-of-pocket cap on Part D drug costs starting in 2025, and it eliminated the coverage gap (the "donut hole") that previously led to thousands of dollars in extra costs mid-year. This is a meaningful improvement for those who qualify for coverage.

Navigating Medicare Part D Formulary

Not every Part D plan formulary is the same. Each plan maintains its own list of covered drugs, and the tier placement of GLP-1 medications varies significantly from plan to plan. Ozempic, for example, appears on some plans as a Tier 3 drug (preferred brand) with a copay in the $45–$90/month range, and on others as Tier 4 (non-preferred brand) with costs that can reach $150–$200 or more before hitting the annual out-of-pocket cap.

During Medicare Open Enrollment (October 15 – December 7 each year), you can switch Part D plans. If you have a diabetes diagnosis and are prescribed a GLP-1, this is one of the most important enrollment decisions you can make. Use the Medicare Plan Finder at medicare.gov to compare plans based on your specific drugs. Enter the exact drug and dosage — the cost difference between plans for the same medication can be hundreds of dollars per year.

Be aware of prior authorization requirements, which are common for GLP-1 drugs even when they are on the formulary. Your prescriber will typically need to document that you have Type 2 diabetes, that your A1C is above a certain threshold, and sometimes that you have tried metformin or other first-line diabetes medications first. Make sure your prescriber's office is familiar with the PA requirements for your specific plan before submitting the prescription.

The Diabetes vs. Obesity Coverage Gap

The exclusion of weight-loss drugs from Medicare coverage dates to 1990s-era legislation that prohibited Medicare Part D from paying for drugs prescribed solely for weight loss. At the time, this made some sense — the available obesity drugs had poor efficacy and real safety concerns. But the GLP-1 medications that exist today are categorically different: they have 15–22% body weight reduction rates in clinical trials and demonstrated cardiovascular benefits.

The result of this outdated exclusion is a significant inequity. A Medicare beneficiary with Type 2 diabetes can access Ozempic or Mounjaro with Part D coverage. Their neighbor with obesity and hypertension but no diabetes diagnosis — who may have an equal or greater medical need — cannot access Wegovy or Zepbound through Medicare at any tier, regardless of their income or health status.

For seniors in this position, the practical options are limited but real. Some clinicians prescribe the diabetes-indicated formulations (Ozempic, Mounjaro) off-label for weight management in Medicare patients, which can allow Part D coverage to apply. This is a legal medical practice, and many Medicare Part D plans will cover these drugs when prescribed for diabetes — even if the treating physician has multiple goals. However, this requires a diabetes diagnosis to be clinically accurate, not fabricated purely for coverage purposes.

Medicare Extra Help and the Low Income Subsidy

If your income and assets are below certain thresholds, you may qualify for Medicare Extra Help — also called the Low Income Subsidy (LIS). This federal program pays most of the out-of-pocket costs for Part D prescription drugs, including GLP-1 medications when they are covered under your plan.

In 2025, individuals with annual income below approximately $23,000 (singles) or $31,000 (couples) and limited assets may qualify. The benefit can reduce your copay for a covered GLP-1 to as little as $4.50 per month for generics or $11.20 for brands at the lowest LIS level. Even at higher LIS levels, your costs are capped well below what standard Part D plans charge.

Apply for Extra Help through Social Security at ssa.gov, or let your State Pharmaceutical Assistance Program (SPAP) help you apply. Many states also operate their own SPAP programs that layer on top of Medicare to fill coverage gaps — programs like EPIC (New York), PACE (Pennsylvania), SHINE (Florida), and others. Eligibility and benefits vary, so check your state's aging services agency for details.

Alternative Cost Reduction Programs

Here is a critical fact that many Medicare beneficiaries do not know: manufacturer savings cards (like Novo Nordisk's savings offer for Ozempic or Eli Lilly's card for Mounjaro) are generally not available to Medicare Part D enrollees. Federal anti-kickback rules prohibit manufacturers from offering these copay programs to federal health program beneficiaries.

However, both Novo Nordisk and Eli Lilly operate income-based Patient Assistance Programs (PAPs) that are open to Medicare beneficiaries who meet income thresholds. Novo Nordisk's Patient Assistance Program provides free Ozempic to eligible patients with income up to 400% of the federal poverty level who have Medicare and cannot afford their medications. Eli Lilly's Insulin Value Program and broader assistance programs similarly provide help for those who qualify.

To access these programs, your prescribing physician typically needs to complete the application on your behalf. Programs like NeedyMeds.org and RxAssist.org maintain comprehensive databases of PAP programs by drug name and can help you identify all programs you might qualify for. Processing times vary from two to eight weeks, so plan ahead and do not wait until you run out of medication to apply.

Some Medicare Advantage (Part C) plans have been more proactive about GLP-1 coverage than traditional Medicare. If you are on a Medicare Advantage plan, review your Evidence of Coverage document carefully, and consider switching plans during open enrollment if a competitor offers better GLP-1 coverage for your diagnosis profile.

What's Changing: Proposed Medicare Expansions

Legislative momentum to expand Medicare coverage to GLP-1 medications for obesity has been building for several years. The Treat and Reduce Obesity Act (TROA) has been reintroduced multiple times in Congress, with bipartisan support. If passed, it would require Medicare to cover FDA-approved obesity medications including Wegovy and Zepbound — removing the 1990s exclusion that currently bars coverage.

In early 2025, the Biden administration proposed a rule that would require Medicare and Medicaid to cover anti-obesity medications. As of this writing, the rule's fate under the new administration is uncertain, and it faces significant budget headwinds given the estimated cost of expanding GLP-1 coverage to tens of millions of Medicare beneficiaries. The Congressional Budget Office has estimated that covering these drugs for Medicare obesity patients could cost $35 billion or more over a decade before accounting for downstream savings from reduced cardiovascular events, hospitalizations, and diabetes complications.

The IRA's drug price negotiation authority is also relevant here. Medicare is now authorized to negotiate directly with manufacturers on high-cost drugs. While GLP-1 medications were not in the first round of negotiations, they are strong candidates for future rounds given their high list prices and high utilization. Negotiated prices could substantially reduce what Medicare and its beneficiaries pay, potentially accelerating the case for expanded coverage.

For now, the most actionable advice for Medicare beneficiaries is to work closely with your prescriber to document all relevant diagnoses accurately, explore Part D plan options during open enrollment, apply for Extra Help if you are income-eligible, and contact manufacturer patient assistance programs if you are struggling with costs. Staying engaged with advocacy organizations like the Obesity Medicine Association and AARP, who are actively pushing for Medicare coverage expansion, can also help advance the policy changes that could benefit millions of seniors.